- Home
- ATXS
as 12-17-2024 4:00pm EST
Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Their second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, or AD, an immune disorder associated with loss of skin barrier function and itching.
| Founded: | 2008 | Country: | United States |
| Employees: | N/A | City: | BOSTON |
| Market Cap: | 584.1M | IPO Year: | 2015 |
| Target Price: | $28.00 | AVG Volume (30 days): | 340.4K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.97 | EPS Growth: | N/A |
| 52 Week Low/High: | $5.88 - $16.90 | Next Earning Date: | 11-13-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Astria Therapeutics Inc. News
ATXS Breaking Stock News: Dive into ATXS Ticker-Specific Updates for Smart Investing
Business Wire
7 days ago
Astria Therapeutics Announces Positive Final Results from Target Enrollment in the ALPHA-STAR Phase 1b/2 Trial of Navenibart for HAE
Business Wire
8 days ago
Astria Therapeutics Announces FDA Clearance of IND Application for STAR-0310, a Monoclonal Antibody OX40 Antagonist for the Treatment of Atopic Dermatitis
Business Wire
15 days ago
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Wire
a month ago
Astria Therapeutics Reports Third Quarter 2024 Financial Results and Provides a Corporate Update
Business Wire
a month ago
Astria Therapeutics to Present at Upcoming Jefferies London Healthcare Conference
Business Wire
a month ago
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Wire
2 months ago
Astria Therapeutics to Present at Upcoming Canadian Society of Allergy and Clinical Immunology Annual Scientific Meeting
Business Wire
2 months ago
Astria Therapeutics to Present at Upcoming American College of Allergy, Asthma, and Immunology Annual Scientific Meeting
Compare ATXS vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ATXS Astria Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.